

Date: June 3, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received an order from Office of Superintendent of Central Tax, Bholakpur, Telangana (“Department”) imposing a penalty of Rs. 40,000/- under applicable provisions of the CGST Act, 2017. The Company is examining the aforesaid Order received from the Department and shall take appropriate steps, including filing of an appeal if required. There is no material impact on financials, operations or other activities of the Company.

The detailed disclosure as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 for aforesaid is enclosed as Annexure I.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Pradeep Chugh
Company Secretary and Compliance Officer

Annexure – I

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Details of event that needs to be provided	Details
1	Name of the authority	Office of Superintendent of Central Tax, Bholakpur, Telangana (“Department”)
2	Nature and details of the action(s) taken, initiated or order(s) passed	<p>Order-in-Original passed u/s 73 of Central Goods and Services Tax Act, 2017 for financial year 2018-19 levying penalty of Rs. 40,000/-.</p> <p>The Tax and interest demand in this matter is below the material threshold limit currently applicable to the Company.</p>
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Order dated April 28, 2024 (received on May 31, 2024)
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	The Department has alleged that there is a mismatch in the credit note figures reported in GSTR-1 vis-à-vis GSTR-9 for FY 2018-19.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible and reason for delay submission	<p>Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified.</p> <p>The Company is exploring various options available to take appropriate steps, including filing of an appeal if required.</p> <p>There is no material impact on financials, operations or other activities of the Company.</p> <p>The Communication was received post working hours on May 31, 2024 and the concerned person who has received the email was travelling and accessed the email on June 3, 2024 and hence being reported on June 3, 2024.</p>

MANKIND PHARMA LIMITED